@article{b8662f7bd955402890c1fb4db418e9d7,
title = "Airway mucosal host defense is key to genomic regulation of cystic fibrosis lung disease severity",
abstract = "Rationale: The severity of cystic fibrosis (CF) lung disease varies widely, even for Phe508del homozygotes. Heritability studies show that more than 50% of the variability reflects non-cystic fibrosis transmembrane conductance regulator (CFTR) genetic variation; however, the full extent of the pertinent genetic variation is not known. Objectives: We sought to identify novel CF disease-modifying mechanisms using an integrated approach based on analyzing “in vivo” CF airway epithelial gene expression complemented with genome-wide association study (GWAS) data. Methods: Nasal mucosal RNA from 134 patients with CF was used for RNA sequencing. We tested for associations of transcriptomic (gene expression) data with a quantitative phenotype of CF lung disease severity. Pathway analysis of CF GWAS data (n = 5,659 patients) was performed to identify novel pathways and assess the concordance of genomic and transcriptomic data. Association of gene expression with previously identified CF GWAS risk alleles was also tested. Measurements and Main Results: Significant evidence of heritable gene expression was identified. Gene expression pathways relevant to airway mucosal host defense were significantly associated with CF lung disease severity, including viral infection, inflammation/inflammatory signaling, lipid metabolism, apoptosis, ion transport, Phe508del CFTR processing, and innate immune responses, including HLA (human leukocyte antigen) genes. Ion transport and CFTR processing pathways, as well as HLA genes, were identified across differential gene expression and GWAS signals. Conclusions: Transcriptomic analyses of CF airway epithelia, coupled to genomic (GWAS) analyses, highlight the role of heritable host defense variation in determining the pathophysiology of CF lung disease. The identification of these pathways provides opportunities to pursue targeted interventions to improve CF lung health.",
keywords = "Cystic fibrosis, Epithelia, Genome, Genome-wide association study, Transcriptome",
author = "Deepika Polineni and Hong Dang and Gallins, {Paul J.} and Jones, {Lisa C.} and Pace, {Rhonda G.} and Stonebraker, {Jaclyn R.} and Commander, {Leah A.} and Krenicky, {Jeanne E.} and Zhou, {Yi Hui} and Harriet Corvol and Cutting, {Garry R.} and Drumm, {Mitchell L.} and Strug, {Lisa J.} and Boyle, {Michael P.} and Durie, {Peter R.} and Chmiel, {James F.} and Fei Zou and Wright, {Fred A.} and O{\textquoteright}Neal, {Wanda K.} and Knowles, {Michael R.}",
note = "Funding Information: Supported by NHLBI grants HL095396 and HL068890, National Institute of Diabetes and Digestive and Kidney Diseases grant P30 DK065988, National Human Genome Research Institute grant R21HG007840, Canadian Institutes of Health Research Open Operating Grants Program (MOP) grant 258916, Cystic Fibrosis Canada (CFC) grant 2626, Genome Canada through the Ontario Genomics Institute (2004-OGI-3-05), Cystic Fibrosis Foundation grants POLINE09FO and BOUCHE15R0, and the Gilead Sciences Research Scholars Program in Cystic Fibrosis. The authors thank the research coordinators at participating sites for their efforts: Julie Avolio, Colette Bucur, Erin Felling, and Douglas Walker. The authors also thank Anthony T. Dang and Michael V. Patrone for their contributions in data analysis support; Alison Williams, Sarah N. Dalrymple, and Hemant Kelkar and Airong Xu (University of North Carolina Center for Bioinformatics) for data management support; Farnoosh Abbas Aghababazadeh for assistance in figure formatting; and Xueliang Guo for thoughtful discussions. Last, the authors thank the Cystic Fibrosis Foundation for the use of its CF Patient Registry data, as well as the participants with CF, their families, their care providers, and the clinic coordinators for their contributions to the registry. The authors are most grateful to every patient and family that participated in this study. Funding Information: Supported by NHLBI grants HL095396 and HL068890, National Institute of Diabetes and Digestive and Kidney Diseases grant P30 DK065988, National Human Genome Research Institute grant R21HG007840, Canadian Institutes of Health Research Open Operating Grants Program (MOP) grant 258916, Cystic Fibrosis Canada (CFC) grant 2626, Genome Canada through the Ontario Genomics Institute (2004-OGI-3-05), Cystic Fibrosis Foundation grants POLINE09FO and BOUCHE15R0, and the Gilead Sciences Research Scholars Program in Cystic Fibrosis. Publisher Copyright: Copyright {\textcopyright} 2018 by the American Thoracic Society.",
year = "2018",
month = jan,
day = "1",
doi = "10.1164/rccm.201701-0134OC",
language = "English",
volume = "197",
pages = "79--93",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
number = "1",
}